Royalty Pharma plc
0 products tracked · names used in filings: Royalty Pharma plc
Upcoming milestones
Royalty Pharma plc: PDUFA target action date
Royalty Pharma plc (RPRX); "obexelimab In August 2026, Zenas BioPharma announced that the FDA accepted for review its Biologics License Application for obexelimab for the treatment of immunoglobulin G4-related disease (IgG4-RD) and assigned a PDUFA target action date of May 27, 2027."; filed 2026-11-04 · source
deucrictibant immediate-release: PDUFA target action date (on-demand treatment of hereditary angioedema attacks)
Royalty Pharma plc (RPRX); deucrictibant; NDA; status: set; "deucrictibant In July 2026, Pharvaris announced that the FDA accepted its NDA for deucrictibant immediate-release for the on-demand treatment of hereditary angioedema attacks and assigned a PDUFA date of April 23, 2027."; filed 2026-08-05 · source
neladalkib: PDUFA target action date (ALK-positive non-small cell lung cancer)
Royalty Pharma plc (RPRX); NDA; status: set; "In May 2026, Nuvalent announced the FDA accepted its NDA for neladalkib for filing and granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) date of November 27, 2026."; filed 2026-08-05 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.